Check out Entire Prescribing Data OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed following autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or right after 3 or maybe more strains of systemic therapy that includes autologou